Cargando…
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
BACKGROUND AND AIMS: The hallmark of non-alcoholic fatty liver disease (NAFLD) is the excessive hepatic lipid accumulation. Currently, no pharmacotherapy exists for NAFLD. However, the glucagon-like peptide-1 receptor agonists have recently emerged as potential therapeutics. Here, we sought to ident...
Autores principales: | Errafii, Khaoula, Al-Akl, Neyla S., Khalifa, Olfa, Arredouani, Abdelilah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173795/ https://www.ncbi.nlm.nih.gov/pubmed/34078383 http://dx.doi.org/10.1186/s12967-021-02885-4 |
Ejemplares similares
-
Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
por: Khalifa, Olfa, et al.
Publicado: (2022) -
Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism
por: Errafii, Khaoula, et al.
Publicado: (2022) -
Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells
por: Khalifa, Olfa, et al.
Publicado: (2023) -
Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern population-based cross-sectional study
por: Al Akl, Neyla S., et al.
Publicado: (2021) -
Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers
por: Khalifa, Olfa, et al.
Publicado: (2020)